Evaluating the effect of oral iron chelators on markers of renal function in beta-thalassemia major

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090111001545N4

Enrollment

Registered

2018-05-05

Start date

2017-08-23

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassaemia Major. Beta thalassemia

Interventions

Intervention 1: Intervention group: treatment with defrasirox. Intervention 2: Intervention group: treatment with defroxamine. Intervention 3: Control group: healthy individuals.

Eligibility

Sex/Gender

All

Age

4 Years to 18 Years

Inclusion criteria

Inclusion criteria: beta thalassemia major patients receiving deferasirox for more than a year beta thalassemia major patients receiving deferoxamine for more than a year healthy control group

Exclusion criteria

Exclusion criteria: previous diagnosis of congenital diseases previous diagnosis of renal functions diseases acute sign and symptoms of acute kidney disease

Design outcomes

Primary

Measure	Time frame
Renal function markers. Timepoint: after on year treatment. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Badeli

Rasht University of Medical Sciences

badeli@gums.ac.ir+98 13 3336 9002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026